NASDAQ:IMMU - Immunomedics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$26.14 +0.14 (+0.54 %)
(As of 07/22/2018 01:09 AM ET)
Previous Close$26.14
Today's Range$25.88 - $26.28
52-Week Range$7.17 - $27.33
Volume1.10 million shs
Average Volume2.16 million shs
Market Capitalization$4.35 billion
P/E Ratio-32.27
Dividend YieldN/A
Beta1.7
Immunomedics logoImmunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody; and a collaboration agreement with University of Wisconsin Carbone Cancer Center to expand IMMU-132 into prostate cancer. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Receive IMMU News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IMMU
CUSIP45290710
Phone973-605-8200

Debt

Debt-to-Equity Ratio2.81
Current Ratio3.94
Quick Ratio3.94

Price-To-Earnings

Trailing P/E Ratio-32.27
Forward P/E Ratio-20.75
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.09 million
Price / Sales1,415.71
Cash FlowN/A
Price / CashN/A
Book Value($0.54) per share
Price / Book-48.41

Profitability

EPS (Most Recent Fiscal Year)($0.81)
Net Income$-153,200,000.00
Net Margins-8,708.96%
Return on EquityN/A
Return on Assets-47.04%

Miscellaneous

Employees138
Outstanding Shares167,350,000
Market Cap$4,351.01

Immunomedics (NASDAQ:IMMU) Frequently Asked Questions

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) announced its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.06. The biopharmaceutical company earned $0.50 million during the quarter, compared to analysts' expectations of $4.27 million. The company's revenue was down 61.5% compared to the same quarter last year. View Immunomedics' Earnings History.

What price target have analysts set for IMMU?

4 Wall Street analysts have issued 1 year price objectives for Immunomedics' stock. Their predictions range from $15.00 to $53.00. On average, they anticipate Immunomedics' stock price to reach $31.50 in the next year. This suggests a possible upside of 20.5% from the stock's current price. View Analyst Ratings for Immunomedics.

What is the consensus analysts' recommendation for Immunomedics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting Immunomedics?

Immunomedics saw a decline in short interest during the month of June. As of June 15th, there was short interest totalling 24,537,779 shares, a decline of 12.2% from the May 31st total of 27,938,918 shares. Based on an average trading volume of 4,391,738 shares, the days-to-cover ratio is presently 5.6 days. Approximately 17.0% of the company's shares are sold short. View Immunomedics' Current Options Chain.

Who are some of Immunomedics' key competitors?

Who are Immunomedics' key executives?

Immunomedics' management team includes the folowing people:
  • Mr. Michael R. Garone, CFO, Principal Accounting Officer & VP of Fin. (Age 59)
  • Mr. Michael F. Pehl, Pres, CEO & Director (Age 53)
  • Ms. Phyllis Parker, Director of Admin.
  • Dr. Chau Cheng, Sr. Director of Investor Relations & Corp. Sec.
  • Dr. William A. Wegener, Chief Medical Officer

Has Immunomedics been receiving favorable news coverage?

Media coverage about IMMU stock has trended somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Immunomedics earned a coverage optimism score of 0.09 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.97 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Immunomedics' major shareholders?

Immunomedics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include SEATTLE GENETICS INC (4.90%), Fred Alger Management Inc. (0.12%) and Amalgamated Bank (0.01%). Company insiders that own Immunomedics stock include Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg, Don C Stark, Mary E Paetzold and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.

Which institutional investors are buying Immunomedics stock?

IMMU stock was purchased by a variety of institutional investors in the last quarter, including Fred Alger Management Inc. and Amalgamated Bank. Company insiders that have bought Immunomedics stock in the last two years include Behzad Aghazadeh and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.

How do I buy shares of Immunomedics?

Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immunomedics' stock price today?

One share of IMMU stock can currently be purchased for approximately $26.14.

How big of a company is Immunomedics?

Immunomedics has a market capitalization of $4.35 billion and generates $3.09 million in revenue each year. The biopharmaceutical company earns $-153,200,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Immunomedics employs 138 workers across the globe.

How can I contact Immunomedics?

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]


MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  240 (Vote Outperform)
Underperform Votes:  197 (Vote Underperform)
Total Votes:  437
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe IMMU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.